Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
BioAmber Inc. (BIOA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2019 SC 13G/A Miller Derek J. reports a 5% stake in BioAmber Inc.
08/08/2019 SC 13G/A Gocong Christopher reports a 5.4% stake in BioAmber, Inc.
07/10/2019 SC 13G Gocong Christopher reports a 5.2% stake in BioAmber, Inc.
07/09/2019 SC 13G Miller Derek J. reports a 5% stake in BioAmber Inc.
02/14/2019 SC 13D/A SOFINNOVA CAPITAL VI FCPR reports a 2.5% stake in BioAmber Inc.
02/08/2019 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 8% stake in BioAmber Inc.
01/03/2019 SC 13G/A SABBY MANAGEMENT, LLC reports a 0.4% stake in BioAmber Inc.
10/26/2018 8-K Asset disposition
Docs: "BioAmber Provides Update on Liquidation Process"
08/14/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "BioAmber Provides Update on Liquidation Process Montreal, Canada, August 9, 2018. BioAmber Inc. announces that following a court order issued on July 31, 2018, the company, along with its monitor, PricewaterhouseCoopers , has initiated a liquidation process pursuant to which offers will be solicited from liquidators and/or strategic buyers to proceed with the liquidation of the company's assets or a recapitalization transaction with the goal of realizing the greatest value on behalf of the company's creditors. Binding offers from the liquidators or strategic buyers must be received by 9 a.m. on August 21st , 2018, and if acceptable offers are received, the company will seek to obtain court approval of the retained offer on August 28 th , 2018 and close the transaction on August 31st , 2018..."
08/01/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "BioAmber Provides Update on Sales Process Montreal, Canada, July 30, 2018. BioAmber Inc. announces that the current stage of the Sales and Investor Solicitation Process has concluded without an acceptable offer having been received from a Qualified Bidder as of the due date of July 27, 2018. The company will now seek to obtain court approval to pursue liquidation as well as alternative offers in order to realize the greatest value on behalf of its creditors. Moving forward, subject to the approval of the court and with support from its monitor or receiver appointed by the court, the company intends to: • solicit liquidators to bid on the acquisition and disposal of the company's assets, including the Sarnia plant; • continue to actively engage with Qualified Bidders and other interested pa..."
06/20/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "BioAmber Receives Favourable Court Ruling and Approval for DIP Financing Montreal, Canada, June 18, 2018. BioAmber Inc. announced today that it has received formal Quebec court approval for debtor-in-possession financing. This funding will enable the execution of the Sales and Investor Solicitation Process that commenced on June 1, 2018, as well as the continued operations of the Sarnia manufacturing facility. Highlights of the court ruling include: • For the SISP, non-binding letters of intent are now due by June 29, 2018, with binding term sheets being due by July 31, 2018; • The stay of proceedings against the petitioners has been extended by the court to July 31, 2018, consistent with the timing of the SISP; • A CAN$3 million DIP financing, provided by Maynbridge Capital, will be disb..."
06/07/2018 SC 13G/A NN Group N.V. reports a 0% stake in BioAmber Inc.
05/09/2018 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/08/2018 8-K Bankruptcy or Receivership, Financial Statements and Exhibits
Docs: "BioAmber Announces Filing for Stay of Proceedings on Creditors Montreal, Canada, May 4, 2018. BioAmber Inc. announces today that it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code and that its two Canadian subsidiaries, BioAmber Sarnia Inc. and BioAmber Canada Inc., filed a Notice of Intention to make a proposal under the Bankruptcy and Insolvency Act , with a view to strengthening the company's financial health and solidifying its long-term business prospects. BioAmber believes filing these procedures is the best way to protect all stakeholders and will best facilitate its efforts to renegotiate its debt and raise the funds needed to continue its operations. The filing of these procedures has the effect of imposing an automatic stay of proceedi..."
04/30/2018 10-K/A Annual Report for the period ended December 31, 2017 [amend]
04/16/2018 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/30/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2018 10-K Annual Report for the period ended December 31, 2017
03/20/2018 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/15/2018 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/09/2018 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/27/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
02/20/2018 SC 13G INTRACOASTAL CAPITAL, LLC reports a 10% stake in BioAmber Inc.
02/16/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "BioAmber Inc. Receives Notice of Delisting by TSX Montreal, Canada, February 16, 2018. BioAmber Inc. announced today that the Toronto Stock Exchange has notified the Company that it has determined to suspend trading in the Company's shares of common stock, effective February 16, 2018, and to delist the Company's securities effective at the close of market on March 16, 2018. These measures were taken due to the Company not meeting the continued listing requirements of the TSX. Notification by the TSX of expedited listing review was announced on February 13, 2018 The Company's shares currently trade on the OTC Pink Sheets. The TSX notification does not affect the Company's business operations or its Securities and Exchange Commission or applicable Canadian reporting requirements, and does no..."
02/16/2018 SC 13G SABBY MANAGEMENT, LLC reports a 8.4% stake in BioAmber Inc.
02/15/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "BioAmber Inc. Receives Notice of Delisting Review by TSX Montreal, Canada, February 13, 2018. BioAmber Inc. announced today that the Toronto Stock Exchange has notified the Company that it is reviewing, on an expedited basis, the Company's eligibility for continued listing. This review results from the Company not being in a position to obtain the approval of the TSX in connection with its registered direct offering announced on February 9, 2018. BioAmber was notified of the listing review on February 12, 2018. A meeting with the continued listing committee of the TSX is scheduled to be held on February 15, 2018 at which the Company may make submissions. Since suspension of trading and delisting of the Company's shares from the TSX is a possible outcome, the Company may seek alternative Ca..."
02/13/2018 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/09/2018 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/08/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between BioAmber Inc. and H.C. Wainwright & Co., LLC",
"Form of Series A Warrant to Purchase Common Stock of BioAmber Inc",
"Form of Pre-Funded Warrant to Purchase Common Stock of BioAmber Inc",
"Opinion of Goodwin Procter LLP",
"BIOAMBER INC. ANNOUNCES PRICING OF US$10 MILLION UNDERWRITTEN PUBLIC OFFERING Montreal, Canada, February 6, 2018. BioAmber Inc. announced today that it has priced an underwritten public offering of an aggregate of 40 million Series A units , with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, and each Series B unit consisting of one pre-funded warrant to purchase one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, at a price to the public of US$0.25 per Series A unit and US$0.24 per Series B unit. The Series A warrants have an exercise price of US$0.25 and a ..."
02/05/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Waiver to Loan Agreement, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto",
"BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING Montreal, Canada, February 5, 2018. BioAmber Inc. announced today that it has commenced an underwritten public offering of its Series A units, with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock. The Company is also offering Series B units, in lieu of Series A units, to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 4.99% of the Company's outstanding common stock following the offering, if they so choose. The Series B units will consist of pre-funded warrants to purchase one share of common stock, Series A warrants to purc..."
02/05/2018 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/26/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Waiver and Third Amending Agreement to Loan Agreement, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto",
"Waiver and Fourth Amending Agreement to Loan Agreement, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto"
01/09/2018 SC 13G/A SABBY MANAGEMENT, LLC reports a 4.8% stake in BioAmber Inc.
11/08/2017 10-Q Quarterly Report for the period ended September 30, 2017
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy